PURPOSE: Parathyroid hormone-related peptide (PTHrP) is the predominant cause of malignancy-associated hypercalcemia. However, its prognostic utility is unclear. We aimed to determine the prognostic value of serum PTHrP levels in patients who had hypercalcemia associated with malignancy. METHODS: In this prospective case series, we evaluated 76 patients with a diagnosis of cancer and hypercalcemia (serum calcium level >/=10.3 mg/dL on at least two occasions). PTHrP levels >/=1 pmol/L were considered elevated. We used multivariate Cox regression analysis to identify factors associated with mortality. RESULTS: Fifty patients (66%) died during follow-up. In a multivariate analysis, higher pretreatment calcium levels and elevated PTHrP levels were associated with increased mortality, with effects of PTHrP varying by age (P = 0.03). Survival was associated with pretreatment calcium levels both in patients over 65 years of age (hazard ratio [HR] per mg/dL = 1.5; 95% confidence interval [CI]: 1.2 to 1.8; P <0.001) and in patients aged 65 years or less (HR = 1.3; 95% CI: 1.1 to 1.5; P = 0.003). Adjusted for pretreatment calcium levels, elevated PTHrP levels were associated with increased mortality in patients aged </=65 years (HR = 3.8; 95% CI: 1.6 to 8.8; P = 0.002), but not in older patients (HR = 0.7; 95% CI: 0.3 to 1.9; P = 0.51). CONCLUSION: PTHrP is a useful prognostic factor in malignancy-associated hypercalcemia, at least in patients aged </=65 years.
PURPOSE:Parathyroid hormone-related peptide (PTHrP) is the predominant cause of malignancy-associated hypercalcemia. However, its prognostic utility is unclear. We aimed to determine the prognostic value of serum PTHrP levels in patients who had hypercalcemia associated with malignancy. METHODS: In this prospective case series, we evaluated 76 patients with a diagnosis of cancer and hypercalcemia (serum calcium level >/=10.3 mg/dL on at least two occasions). PTHrP levels >/=1 pmol/L were considered elevated. We used multivariate Cox regression analysis to identify factors associated with mortality. RESULTS: Fifty patients (66%) died during follow-up. In a multivariate analysis, higher pretreatment calcium levels and elevated PTHrP levels were associated with increased mortality, with effects of PTHrP varying by age (P = 0.03). Survival was associated with pretreatment calcium levels both in patients over 65 years of age (hazard ratio [HR] per mg/dL = 1.5; 95% confidence interval [CI]: 1.2 to 1.8; P <0.001) and in patients aged 65 years or less (HR = 1.3; 95% CI: 1.1 to 1.5; P = 0.003). Adjusted for pretreatment calcium levels, elevated PTHrP levels were associated with increased mortality in patients aged </=65 years (HR = 3.8; 95% CI: 1.6 to 8.8; P = 0.002), but not in older patients (HR = 0.7; 95% CI: 0.3 to 1.9; P = 0.51). CONCLUSION:PTHrP is a useful prognostic factor in malignancy-associated hypercalcemia, at least in patients aged </=65 years.
Authors: Jiarong Li; Andrew C Karaplis; Dao C Huang; Peter M Siegel; Anne Camirand; Xian Fang Yang; William J Muller; Richard Kremer Journal: J Clin Invest Date: 2011-11-07 Impact factor: 14.808
Authors: Nicolas Penel; Sylvain Dewas; Philippe Doutrelant; Stéphanie Clisant; Yazdan Yazdanpanah; Antoine Adenis Journal: Support Care Cancer Date: 2007-08-21 Impact factor: 3.603
Authors: Shreyashee Mallik; Girijasankar Mallik; Shireen Teves Macabulos; Andrew Dorigo Journal: Support Care Cancer Date: 2015-10-06 Impact factor: 3.603
Authors: Anne Camirand; Ibtihal Fadhil; Aimée-Lee Luco; Benoît Ochietti; Richard B Kremer Journal: Am J Cancer Res Date: 2013-11-01 Impact factor: 6.166
Authors: Jason R Pitarresi; Robert J Norgard; Anna M Chiarella; Kensuke Suzuki; Basil Bakir; Varun Sahu; Jinyang Li; Jun Zhao; Benoît Marchand; Maximilian D Wengyn; Antony Hsieh; Il-Kyu Kim; Amy Zhang; Karine Sellin; Vivian Lee; Shigetsugu Takano; Yoji Miyahara; Masayuki Ohtsuka; Anirban Maitra; Faiyaz Notta; Richard Kremer; Ben Z Stanger; Anil K Rustgi Journal: Cancer Discov Date: 2021-02-15 Impact factor: 38.272